General Information of Drug (ID: DM1GE67)

Drug Name
GS-4224
Synonyms
Methyl Pyridazine-4-carboxylate; 34231-77-1; PYRIDAZINE-4-CARBOXYLIC ACID METHYL ESTER; 4-PYRIDAZINECARBOXYLIC ACID, METHYL ESTER; MFCD09953488; ACMC-1AJNN; methyl 4-pyridazinecarboxylate; methylpyridazine-4-carboxylate; SCHEMBL1421640; DTXSID30498310; AMY24958; BCP22435; ANW-50355; ZINC12359421; AKOS015854403; Methyl pyridazine-4-carboxylate, 97%; AC-4414; CS-W003697; PB31452; 4-Pyridazinecarboxylic acid methyl ester; AK-48857; SY004472; AB0024323; DB-030309; FT-0717698; W5569; S-2990; J-522632
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 138.12
Logarithm of the Partition Coefficient (xlogp) -0.3
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C6H6N2O2
IUPAC Name
methyl pyridazine-4-carboxylate
Canonical SMILES
COC(=O)C1=CN=NC=C1
InChI
InChI=1S/C6H6N2O2/c1-10-6(9)5-2-3-7-8-4-5/h2-4H,1H3
InChIKey
IJFLWNYKGMQQOW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
12439252
CAS Number
34231-77-1
TTD ID
DS6VD0
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death 1 ligand 1 (PD-L1) DTT CD274 4.38E-07 0.37 2.1
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04049617) Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Gilead Sciences.